CRIS Current Research Information System

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.505
EU - Europa 2.347
AS - Asia 1.438
AF - Africa 141
SA - Sud America 15
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 7.453
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.490
GB - Regno Unito 673
VN - Vietnam 492
SE - Svezia 481
CN - Cina 471
DE - Germania 297
SG - Singapore 265
IT - Italia 258
IN - India 144
IE - Irlanda 100
UA - Ucraina 88
FR - Francia 87
RU - Federazione Russa 86
CH - Svizzera 79
EE - Estonia 61
ZA - Sudafrica 57
TG - Togo 47
FI - Finlandia 34
BG - Bulgaria 25
HR - Croazia 19
CI - Costa d'Avorio 17
BE - Belgio 16
NG - Nigeria 16
CA - Canada 15
IR - Iran 13
JO - Giordania 10
BR - Brasile 9
GR - Grecia 8
JP - Giappone 8
PL - Polonia 8
LB - Libano 7
ES - Italia 6
ID - Indonesia 6
HK - Hong Kong 5
NL - Olanda 5
CL - Cile 4
CZ - Repubblica Ceca 4
LT - Lituania 4
SC - Seychelles 4
AU - Australia 3
TR - Turchia 3
UZ - Uzbekistan 3
BD - Bangladesh 2
HU - Ungheria 2
IS - Islanda 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PE - Perù 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AT - Austria 1
BY - Bielorussia 1
EU - Europa 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
TM - Turkmenistan 1
Totale 7.453
Salva come PNG Salva come JPEG
Città #
Southend 605
Fairfield 448
Chandler 344
Dong Ket 310
Ashburn 286
Singapore 234
Woodbridge 228
Houston 221
Wilmington 203
Seattle 190
Ann Arbor 173
Santa Clara 161
Princeton 141
Cambridge 133
Dublin 100
Boardman 95
Bern 76
Nanjing 70
Westminster 63
Padova 60
Lomé 47
Jacksonville 45
Berlin 42
New York 41
Jinan 40
Beijing 38
Bologna 36
Helsinki 34
San Diego 32
Changsha 31
Florence 28
Saint Petersburg 27
Shenyang 27
Hebei 26
Bremen 25
Sofia 25
Los Angeles 24
Hyderabad 22
Turin 21
Redwood City 19
Abidjan 17
Jiaxing 17
Medford 17
Abeokuta 16
Brussels 15
Dearborn 15
Ningbo 15
Norwalk 15
Toronto 14
Mülheim 13
Nanchang 13
Redmond 13
Zhengzhou 13
Taizhou 12
Hangzhou 11
Milan 11
Amman 10
Haikou 9
Falls Church 8
Guangzhou 8
Mountain View 8
Olalla 8
Phoenix 8
Taiyuan 8
Lanzhou 7
Shanghai 7
São Paulo 7
Tianjin 7
Jakarta 6
London 6
Monmouth Junction 6
Pune 6
Rijeka 6
San Francisco 6
Warsaw 6
Andover 5
Bühl 5
Des Moines 5
Falconara Marittima 5
Fuzhou 5
Wayne 5
Xi'an 5
Zanjan 5
Fremont 4
Henderson 4
Kunming 4
Mahé 4
Quanzhou 4
Foshan 3
Hefei 3
Kuban 3
Leawood 3
Paris 3
Recanati 3
Reggio Emilia 3
San Venanzo 3
Tokyo 3
Ardabil 2
Athens 2
Auckland 2
Totale 5.228
Salva come PNG Salva come JPEG
Nome #
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 197
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 197
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 194
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 182
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 181
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 156
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 155
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 154
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 153
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 153
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 151
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 150
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 146
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 145
RALE051: a novel established cell line of sporadic Burkitt lymphoma 143
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 143
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 136
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 136
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 136
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 134
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 132
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 130
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 128
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 127
Treatment of colorectal cancer liver metastases 124
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 123
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 122
Bendamustine: role and evidence in lymphoma therapy, an overview. 121
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 121
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 120
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 120
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 119
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 118
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 118
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 117
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 116
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 116
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 115
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 111
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 110
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 110
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 108
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 107
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 106
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 104
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 104
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 104
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 99
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 98
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 94
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE. 85
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 85
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 85
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 85
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 81
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 81
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 81
null 75
Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results 65
METRONOMIC CAPECITABINE IN ADVANCED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS. 61
The tratment of liver metastases from colorectal cancer: questions more than answers? 60
Liver metastases from colorectal cancer 57
Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). 44
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 37
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 30
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 12
Totale 7.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.815
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.815
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.071 0 0 0 0 0 0 232 239 283 117 91 109
2020/20211.088 177 62 33 28 24 66 7 45 93 34 52 467
2021/20221.385 196 53 104 144 108 71 45 71 48 89 245 211
2022/20231.492 197 200 83 189 96 120 29 81 198 48 115 136
2023/2024360 28 62 14 45 22 91 19 14 9 28 6 22
2024/2025756 43 211 109 93 252 43 5 0 0 0 0 0
Totale 7.608